Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Bristol-Myers Squibb (BMS)

Status and phase: Withdrawn; Phase 1

Conditions: Healthy Participants

Treatments: Drug: BMS-986235 (Treatment A); Drug: Rifampin (Treatment B)

Study type: Interventional

Funder types: Industry

Identifiers

NCT04301310

CV018-023

Details and patient eligibility

About

The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history.
• Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening
• Males must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

• Women of childbearing potential (WOCBP)
• Known previous exposure to BMS-986235
• History of any significant drug allergy

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Treatment Group

Experimental group

Treatment:

Drug: Rifampin (Treatment B)

Drug: BMS-986235 (Treatment A)